Liposomal encapsulated anti-cancer drugs

被引：259

作者：

Hofheinz, RD

Gnad-Vogt, SU

Beyer, U

Hochhaus, A

机构：

[1] Heidelberg Univ, Fak Klin Med Mannheim, Med Klin 3, Onkol Zentrum, D-68167 Mannheim, Germany

[2] Medac GMBH, Wedel, Germany

来源：

ANTI-CANCER DRUGS | 2005年 / 16卷 / 07期

关键词：

D O I：

10.1097/01.cad.0000167902.53039.5a

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anticancer agents.

引用

页码：691 / 707

页数：17

共 127 条

[121] Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys [J].